TARS - Tarsus Pharmaceuticals  - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TARS is currently covered by 7 analysts with an average price target of $64.33. This is a potential upside of $21.35 (49.67%) from yesterday's end of day stock price of $42.98.

Tarsus Pharmaceuticals 's activity chart (see below) currently has 15 price targets and 40 ratings on display. The stock rating distribution of TARS is 86.21% BUY and 13.79% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 51.46% with an average time for these price targets to be met of 425.5 days.

Highest price target for TARS is $84, Lowest price target is $51, average price target is $63.43.

Most recent stock forecast was given by ANDREA TAN from GOLDMAN SACHS on 05-May-2025. First documented stock forecast 10-Nov-2020.

Currently out of the existing stock ratings of TARS, 25 are a BUY (86.21%), 4 are a HOLD (13.79%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$51

$8.02 (18.66%)

$41

19 days ago
(05-May-2025)

2/4 (50%)

$3 (6.25%)

19

Buy

$84

$41.02 (95.44%)

$78

22 days ago
(02-May-2025)

3/5 (60%)

$36.64 (77.36%)

457

Buy

$73

$30.02 (69.85%)

$61

2 months 28 days ago
(26-Feb-2025)

7/10 (70%)

$30.44 (71.52%)

623

Buy

$60

$17.02 (39.60%)

$62

2 months 28 days ago
(26-Feb-2025)

2/5 (40%)

$17.44 (40.98%)

547

Buy

$72

$29.02 (67.52%)

$65

4 months 2 days ago
(22-Jan-2025)

2/8 (25%)

$23.89 (49.66%)

630

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TARS (Tarsus Pharmaceuticals ) average time for price targets to be met?

On average it took 425.5 days on average for the stock forecasts to be realized with a an average price target met ratio 51.46

Which analyst has the current highest performing score on TARS (Tarsus Pharmaceuticals ) with a proven track record?

EDDIE HICKMAN

Which analyst has the current lower performing score on TARS (Tarsus Pharmaceuticals ) with a proven track record?

ANDREA TAN

Which analyst has the most public recommendations on TARS (Tarsus Pharmaceuticals )?

Eddie Hickman works at GUGGENHEIM and has 9 price targets and 7 ratings on TARS

Which analyst is the currently most bullish on TARS (Tarsus Pharmaceuticals )?

Dane Leone with highest potential upside - $51.89

Which analyst is the currently most reserved on TARS (Tarsus Pharmaceuticals )?

Anthony Petrone with lowest potential downside - $1.02

Tarsus Pharmaceuticals  in the News

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference...

Tarsus Pharmaceuticals Inc (TARS) Q1 2025 Earnings Call Highlights: Record Sales Surge and ...

Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tarsus Pharmaceuticals Inc (NASDAQ:TARS) reported a significant year-over-year increase of 217% in sales for their product Exteny, generating over $78 million in the first quarter of 2025. The company has achieved broad...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?